openPR Logo
Press release

Biliary Tract Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

05-08-2024 01:34 AM CET | Health & Medicine

Press release from: ABNewswire

Biliary Tract Cancer Pipeline Outlook, FDA Approvals, Clinical

DelveInsight's, "Biliary Tract Cancers Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Biliary Tract Cancers Pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Biliary Tract Cancer Pipeline Report

* DelveInsight's Biliary Tract Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for treatment.
* The leading Biliary Tract Cancer Companies working in the market include Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others.
* Promising Biliary Tract Cancer Therapies in the various stages of development include Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others.
* May 2024:- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins- Tumor Microenvironment Features of Response to Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers. The purpose of this study is to determine the safety of peri-operative gemcitabine, cisplatin, and pembrolizumab in patients with BTC, as well as whether the combination of gemcitabine, cisplatin, and pembrolizumab (gem/cis/pembro) is feasible and lead to pathologic responses.
* May 2024:- Eli Lilly and Company- A Phase 1/2 Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors. The purpose of this study is to find out whether the study drug, LY3537982, is safe and effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients must have already received or were not able to tolerate the standard of care, except for specific groups who have not had cancer treatment. The study will last up to approximately 4 years.
* April 2024- AstraZeneca- A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE). This study involves assessing the safety and efficacy of durvalumab in combination with different gemcitabine-based chemotherapy regimens as first line therapy for aBTC. The target population of interest in this study is participants with aBTC who are greater than or equal to 18 years of age and above legal age per local regulations with WHO/ECOG PS of 0 to 2 at enrolment and who are not eligible for locoregional therapy.

Request a sample and discover the recent advances in Biliary Tract Cancer @ Biliary Tract Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Biliary Tract Cancer Overview

Biliary tract cancer is a cancer that forms in the cells of the bile ducts, gallbladder or ampulla of Vater. Cancer of the bile ducts is called cholangiocarcinoma and is classified depending on which part of the bile duct the cancer develops into intrahepatic (affects bile ducts within the liver), hilar (occurs at the junction of the left and right hepatic ducts) and extrahepatic (affects the common bile duct outside the liver) sharing different genetic, risk factors and clinical presentation.

Biliary tract cancer: Emerging Drugs

* MRG 002: Miracogen
* Disitamab vedotin: Yantai Rongchang Pharmaceutical
* Envafolimab: Alphamab Oncology
* DKN-01: Leap Therapeutics

Learn more about Biliary Tract Cancer in clinical trials @ Biliary Tract Cancer Drugs [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Biliary Tract Cancer Therapeutics Assessment

There are approx. 80+ Biliary Tract Cancer companies are developing Biliary Tract Cancer therapies. The Biliary Tract Cancer companies with their Biliary Tract Cancer drug candidates in the most advanced stage, i.e. phase II/III include, SMT Bio Co., Ltd.

DelveInsight's Biliary Tract Cancer Pipeline Report covers around 80+ products under different phases of clinical development like

* Late-stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates

Discover more about Biliary Tract Cancer in development @ Biliary Tract Cancer Clinical Trials [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Biliary Tract Cancer Companies

Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others

The Biliary Tract Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Biliary Tract Cancer Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

To learn more about Biliary Tract Cancer, visit @ Biliary Tract Cancer Segmentation [https://www.delveinsight.com/sample-request/biliary-tract-cancers-btcs-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Biliary Tract Cancer Pipeline Report

* Coverage- Global
* Biliary Tract Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Biliary Tract Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Biliary Tract Cancer Companies- Yantai Rongchang Pharmaceutical, RemeGen, EMD Serono, SMT bio Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., InnoPharmax Inc., Lee's Pharmaceutical Limited, Hoffmann-La Roche, Shanghai Miracogen Inc., Zymeworks Inc., Bristol-Myers Squibb, Eli Lilly and Company, Ipsen, Threshold Pharmaceuticals, Leap Therapeutics, Hutchison Medipharma Limited, Array BioPharma, Redx Pharma Plc, Compass Therapeutics, Lee's Pharmaceutical Limited, and others
* Biliary Tract Cancer Therapies- Nivolumab, Gemcitabine, and S-1, Gemcitabine, cisplatin, Pembrolizumab, Sargramostim, oxaliplatin, KN035 plus Gemcitabine & oxaliplatin, and others.

Table of Content

* Introduction
* Executive Summary
* Biliary Tract Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Biliary Tract Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Envafolimab: Alphamab Oncology
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* SMT-NK: SMT bio Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* HA121-28: CSPC ZhongQi Pharmaceutical Technology
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* ZKAB001: Lee's Pharmaceutical Limited
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Biliary Tract Cancer Key Companies
* Biliary Tract Cancer Key Products
* Biliary Tract Cancer- Unmet Needs
* Biliary Tract Cancer- Market Drivers and Barriers
* Biliary Tract Cancer- Future Perspectives and Conclusion
* Biliary Tract Cancer Analyst Views
* Biliary Tract Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=biliary-tract-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Biliary Tract Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated) here

News-ID: 3487984 • Views:

More Releases from ABNewswire

Massage Minneapolis by Halo Healing Therapies Co.: Serving Golden Valley, St. Louis Park, Hopkins & New Hope Near Brookview Park, West End, Mainstreet Hopkins & Northwood Park
Massage Minneapolis by Halo Healing Therapies Co.: Serving Golden Valley, St. Lo …
Halo Healing Therapies Co. in North Loop Minneapolis provides expert therapeutic massage for clients across Golden Valley, St. Louis Park, Hopkins & New Hope. With over 25 years of experience, Halo offers deep tissue, couples, sports, and restorative massage tailored to the active Minneapolis lifestyle. Conveniently located near landmarks like Brookview Park, The West End, Mainstreet Hopkins, and Northwood Park, Halo delivers care that relieves tension, supports recovery, & enhances
Red Teaming vs Penetration Testing: Understanding the Difference
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence. A clearer view of pentest vs red team helps organisations make better
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen Regional Presence
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen …
West Chester, PA - Suburban Solutions [https://suburbansolutions.com/], a highly trusted and fast-growing moving company serving the Greater Philadelphia and Washington, DC regions, is proud to announce the opening of its newest location at 1271 Upton Cir, West Chester, PA 19380. This expansion marks an important step in the company's ongoing mission to provide dependable and accessible relocation support to more communities across Pennsylvania. With this new branch, Suburban Solutions Moving aims
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Support for Global Brands
12-12-2025 | Sports
ABNewswire
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Sup …
Shenzhen LSLONG Garments Co., Ltd., a global leader in apparel manufacturing, has officially unveiled its new Premium Custom Polo Shirt [https://www.lslt-shirt.com/polo-shirt-categories/] Collection, combining advanced fabrics, innovative designs, and end-to-end customization solutions. This launch underscores LSLONG's 25 years of experience delivering high-quality OEM and ODM apparel services to brands across more than 50 countries. The collection aims to empower brands with versatile, stylish, and performance-driven Polo shirts while providing comprehensive support

All 5 Releases


More Releases for Biliary

Global Metal Pancreatic Biliary Stent Market Size by Application, Type, and Geog …
According to Market Research Intellect, the global Metal Pancreatic Biliary Stent market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The metal pancreatic biliary stent market is witnessing consistent growth due to the rising prevalence of
Major Market Share Shift in Biliary Catheters Industry: Advancements In Biliary …
What Is the Forecasted Market Size and Growth Rate for the Biliary Catheters Market? The market size for biliary catheters has experienced robust growth in recent years. There is an expected growth from $3.42 billion in 2024 to $3.75 billion in 2025, corresponding to a compound annual growth rate (CAGR) of 9.7%. Factors like increased occurrences of biliary tract ailments, the popularity of minimally invasive procedures, a growing aging population, more
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Biliary Stents Market - Unleashing Flow: Empowering Biliary Health with Innovati …
Newark, New Castle, USA - new report, titled Biliary Stents Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Biliary Stents market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Biliary Stents market. The report offers an overview of the market, which
High Prevalence of Biliary Diseases Across the Globe is Driving the Biliary Sten …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.
Rise in Surgical Procedures of Biliary Diseases is Expected to Boost the Biliary …
Stent is referred as plastic or metal tube inserted in human body into lumen or duct to keep the passage open. Various types of stents such as expandable stents and simple plastic stents are used for various purposes. Different types of stents such as coronary, vascular, and biliary stents are employed for various purposes. ‘Biliary’ is referred to the bile duct, which is a long tube-like structure carrying bile fluid.